Nasdaq · Healthcare
Pacira BioSciences, Inc. (PCRX)
As-reported financials and recent SEC filings for Pacira BioSciences, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$726.4M
Net income
$7.0M
Net margin
1.0%
Diluted EPS
$0.16
ROE
1.0%
P/E (TTM)
194.2×
Market cap
$993.1M
Debt / equity
0.5×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $726.4M | $701.0M | $675.0M | $666.8M | $541.5M |
| Gross profit | $576.7M | $530.5M | $490.3M | $467.5M | $401.3M |
| Operating income | $19.2M | $-73.4M | $87.7M | $60.0M | $89.9M |
| Net income | $7.0M | $-99.6M | $42.0M | $15.9M | $42.0M |
| Diluted EPS | $0.16 | $-2.15 | $0.89 | $0.34 | $0.92 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
1442026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →Go deeper on PCRX
Search Pacira BioSciences, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.